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Important differences have been demonstrated in laboratory parameters from healthy per-
sons in different geographical regions and populations, mostly driven by a combination of
genetic, demographic, nutritional, and environmental factors. Despite this, European and
North American derived laboratory reference intervals are used in African countries for pa-
tient management, clinical trial eligibility, and toxicity determination; which can result in mis-
classification of healthy persons as having laboratory abnormalities.
Methods
An observational prospective cohort study known as the Kisumu Incidence Cohort Study
(KICoS) was conducted to estimate the incidence of HIV seroconversion and identify deter-
minants of successful recruitment and retention in preparation for an HIV vaccine/prevention
trial among young adults and adolescents in western Kenya. Laboratory values generated
from the KICoS were compared to published region-specific reference intervals and the
2004 NIH DAIDS toxicity tables used for the trial.
Results
About 1106 participants were screened for the KICoS between January 2007 and June
2010. Nine hundred and fifty-three participants aged 16 to 34 years, HIV-seronegative, clini-
cally healthy, and non-pregnant were selected for this analysis. Median and 95% reference
intervals were calculated for hematological and biochemistry parameters. When compared
with both published region-specific reference values and the 2004 NIH DAIDS toxicity table,
it was shown that the use of locally established reference intervals would have resulted in
fewer participants classified as having abnormal hematological or biochemistry values com-
pared to US derived reference intervals from DAIDS (10% classified as abnormal by local
parameters vs.>40% by US DAIDS). Blood urea nitrogen was most often out of range if US
based intervals were used:<10% abnormal by local intervals compared to>83% by US
based reference intervals.
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Conclusion
Differences in reference intervals for hematological and biochemical parameters between
western and African populations highlight importance of developing local reference intervals
for clinical care and trials in Africa.
Introduction
The burden of diseases such as HIV/AIDS, tuberculosis, and malaria is heaviest in sub-Saharan
Africa compared to the rest of the world [1, 2]. For example, sub-Saharan Africa has the highest
prevalence and incidence of HIV infection globally. As such, a major of many recent HIV pre-
vention, care and treatment initiatives are being conducted within the region [3, 4]. including
most phase I ⁄ IIB HIV-1 vaccine trials [5].
With increasing clinical trials in sub-Saharan Africa to combat these diseases, there is a
need for accurate clinical laboratory reference intervals for appropriate participant screening,
disease progression monitoring and evaluation of possible clinical trial-associated toxicity and
adverse events [6]. Reference intervals are important for guiding patient treatment and man-
agement as well as identifying abnormal hematologic values [7]. For example, the complete
blood count and CD4 determination are important laboratory tests in HIV-endemic regions
[8]. The level of hemoglobin concentration has utility as a prognostic indicator while CD4 is
used to make decisions regarding initiation of antiretroviral drugs and to monitor disease pro-
gression. These tests require accurate reference intervals for correct interpretation of laboratory
results. However, currently used reference intervals in many countries in sub-Saharan Africa
are derived from populations in Europe and North America [6, 9]. Since hematologic parame-
ters are affected not only by individual factors such as age, sex and lifestyle, but also by popula-
tion and ecological factors such as ethnic background, climate, exposure to pathogens and
altitude, they vary not only between individuals but also between populations [10]. Thus, there
is not a universal definition of ‘normal’ hence it is important to define reference intervals that
are suited to the particular population of interest [10]. A few studies conducted in Africa over
the last decade have highlighted differences in hematologic parameters between the local popu-
lation and Caucasian populations in Europe and North America [11–15]. More recently, a
study highlighted differences in hematological and biochemistry values between adolescent
and young adult males [15]. Despite these recorded inter-population differences in reference
values for different geographical regions, few data exist in Africa to provide locally-derived val-
ues [7, 12, 13, 16].
Despite these recorded differences, the Division of AIDS (DAIDS) National Institute of
Health toxicity tables [17], are still used for grading the severity of adult and pediatric adverse
events, whether or not they are considered to be related to the study intervention. This leads to
unnecessary exclusion of would be participants misclassified as having abnormal hematologic
parameters thereby escalating operational costs especially in phase I safety trials where there
may not be a control group [18–20]. This may also lead to improper patient management
through misclassification of adverse events. Due to these differences, there is a need to develop
and test locally-derived age specific reference intervals within African populations.
While it is desirable to generate reference intervals for different populations, the procedure
remains a challenge due to the prohibitive cost involved in performing these studies and the
limitation in identifying suitable healthy reference individual. Thus, the recommendation by
the Clinical and Laboratory Standards Institute (CLSI) that all diagnostic laboratories must
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determine and maintain their own reference interval for each laboratory parameter is impracti-
cal. CLSI further recommends that if it is not possible to establish the detailed reference studies,
then validation of published reference intervals can be performed using own methodology for
the population served by the laboratory. Zeh et al have recently established reference intervals
for use in western Kenya [15]. These intervals were generated from a study conducted on 13–34
year old, clinically healthy, HIV-seronegative, non-pregnant residents of western Kenya. Be-
cause the established reference intervals were from a population in Siaya County in western
Kenya, our aim was to validate these established reference intervals for use in Kisumu County
of western Kenya. We also retrospectively determined the proportion of participants in an ob-
servational prospective cohort study known as the Kisumu Incidence Cohort Study (KICoS),
who would be misclassified as having abnormal hematological parameters using the established




This analysis utilized 953 samples obtained from 1106 participants screened in the KICoS con-
ducted between January 2007 and June 2010 at the KEMRI/CDC Clinical Research Center
(CRC) within New Nyanza Provincial General Hospital, Kisumu. The laboratory where the
study was conducted is accredited by the South African National Accreditation System [21].
KiCoS was an observational prospective cohort study designed to estimate the incidence of
HIV seroconversion and to identify determinants of successful recruitment and retention in
preparation for an HIV vaccine or prevention trial among young adults and adolescents in Ki-
sumu, western Kenya. Healthy adolescent (16–17 years) and young adult (18–34 years) resi-
dents of Kisumu who reported having sexual intercourse at least once in the past three months
were eligible for the study. The study was conducted in the catchment area of Kisumu, a city of
approximate population of 578,865 as projected by central bureau of statistics by 2006 in west-
ern Kenya [22]. All participants underwent screening for HIV-1 and HSV-2 among other sexu-
ally transmitted infections. Signs and symptoms were collected both in a self administered
Audio Computer Assisted Self Interview (ACASI) (for STI symptoms) and a clinician adminis-
tered Computer Assisted Personal Interview (CAPI) for all other symptoms. Blood samples
were collected for complete blood count, HIV and HSV-2 testing with laboratory results.
Ethical approval
Ethical approval for the study was obtained from KEMRI and CDC ethics review committee/
institutional review board. Written informed consent was obtained from each participant prior
to study initiation. Minors (<18 years of age) were classified as “mature” or “non-mature”
using legal definitions [23]. Mature minors could consent to study participation as they would
for HIV counseling and testing in Kenya. Non-mature minors went through a two-step written
consent process involving consent from the parent or guardian followed by written individual
assent from the minor.
Blood collection and HIV serology
Whole blood was collected in EDTA vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ)
and transported to the KEMRI/CDC HIV-research laboratory for processing and analysis
within six hours of specimen collection. HIV status was determined from whole blood using
HIV rapid test kits as follows: Determine (Abbot Laboratories, Tokyo, Japan), and Unigold
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(Trinity Biotech Plc, Bray, Ireland), with Bioline (Standard Diagnostics Inc., Korea) as a
tie breaker.
Pregnancy testing
A urine pregnancy test was administered to all females who were not visibly pregnant, using
First Sign HCG One Step (UNIMED International, Inc., South San Francisco, CA, USA).
Hematological analysis
Absolute white blood cell counts and percentages for leukocytes (WBC) with differentials
(neutrophils, lymphocytes, monocytes, eosinophils, and basophils), erythrocytes (RBC) with
parameters (hemoglobin (Hb), hematocrit (Hct), MCV, and MCH), and platelet counts were
determined from whole blood using a Coulter ACT 5Diff CP analyzer (Beckman Coulter,
France). This was performed within 24 hours of sample collection as recommended by
the manufacturer.
Biochemistry analysis
Clinical chemistries were analyzed from serum obtained from serum separation tubes (Becton
Dickinson, Franklin Lakes, NJ). Samples were analyzed for alanine aminotransferase (ALT),
creatinine (Cr), and blood urea nitrogen (BUN) using the Cobas Integra 400 plus biochemistry
analyzer (Roche, Germany) per the manufacturer’s instructions.
Quality Control
Quality control protocols included running known standards each day before testing samples.
In addition, the laboratory is enrolled in external quality assurance testing programs with the
College of American Pathologists (lymphocyte immunophenotyping, hematology, and clinical
chemistry) and the United Kingdom National External Quality Assurance Service (lymphocyte
immunophenotyping). The laboratory has satisfactory performance in UK NEQAS (Lympho-
cyte Immunophenotyping) and CAP Clinical Chemistry as well as CAP Hematology over the
past three years.
Statistical analysis
Data were collected on optical character recognition (OCR) enabled forms and entered with
scanners. Cross-checking and data cleaning was performed regularly We followed the guide-
lines of the Clinical Laboratory Standards Institute (CLSI, Wayne, PA, USA) for reference in-
terval determination [10]. While these guidelines are meant for establishing new reference
intervals, the basic principles also apply to validation of reference intervals [8]. The median
and the 2.5 and 97.5 percentiles were calculated for each hematological parameter. Study par-
ticipants were partitioned into two age groups: those 17 and younger (adolescents) and those
18 and older (young adults) and analyzed using SAS v9.1 (Cary, NC, USA). The Wilcoxon test
was used to compare hematological parameters between the two age groups separately for
males and females and to compare males and females separately by age group. A two-sided P
value of0.05 was considered significant.
We compared our data against reference intervals from the established reference intervals
for western Kenya (Table 1), the Massachusetts General Hospital (MGH), USA reference inter-
vals and the U.S. NIH Division of AIDS (DAIDS) toxicity tables, to determine the number
(and percentage) of study participants who had values outside the established reference inter-
vals (2.5 to 97.5 percentiles) or who had any adverse events as graded by the DAIDS criteria.
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Results
Sample collection results
Out of 1106 participants screened for eligibility, 534 (48.3%) were males while 572 (51.7%)
were females. Following screening, a total of 153 (13.8%) participants was excluded of which
125 (81.7%) were HIV-1 infected, 20 (13.1%) were pregnant and 8 (5.2%) both HIV-1 infected
and pregnant. Thus, 499 (93.4%) male and 454 (79.4%) clinically healthy female participants
were selected for this analysis. Of the male participants, 22.0% (110) were adolescents and
78.0% (389) were young adults while adolescents and young adults constituted 29.1% (132)
and 70.9% (322) of the female participants respectively. The number of participants tested for
each parameter was within the sample size (N = 120) recommended by the CLSI for the estab-
lishment of reference intervals except the male adolescent group which had 110 participants.
However all gender and age groups had sample size above the number required for reference
interval transference (N = 60) [10].
Hematology and chemistry reference intervals
Tables 2 and 3 summarizes the calculated median and 95th percentile reference interval for he-
matological and biochemistry parameters for adolescents and young adults respectively ob-
tained from this study. The reference intervals were generally comparable although our upper
reference limit for some parameters was slightly higher than those of the established reference
intervals. There were significant differences in Hb, RBC, Hct, creatinine, ALT and BUN
Table 1. Hematological, immunologic and biochemistry reference intervals (median and 95th-percentile) stratified by age and gender from a 13–34
years old cohort in rural western Kenya (2003–2005) [15].
Age 13–17 years Age 18–34 years
Parameter Male Female Male Female
RBC (106 Cells/μl) 4.9 (4.1–5.8) 4.7 (3.3–5.4) 5.3 (4.3–6.5) 4.5 (3.4–5.7)
Hb (g/dL) 13.1(10.6–15.6) 12.2 (8.1–14.2) 14.2 (11.4–16.9) 12.1 (8.0–14.2)
HCT (%) 38.8 (29.3–48.1) 35.6 (24.8–43.1) 41.7 (32.6–51.5) 35.8 (23.2–44.3)
MCV (fL) 79 (62–92) 78 (57–91) 80 (55–98) 79 (60–94)
PLT (103 cells/μl) 224 (103–386) 233 (134–439) 201 (102–307) 220 (88–439)
WBC(103 cells/μl) 5.6 (3.3–8.3) 5.2 (3.9–10.2) 5.3 (2.5–7.4) 5.6 (3.3–9.7)
Ne (103 cells/μl) 1.9 (0.8–5.0) 2.0 (1.1–3.1) 2.0 (0.8–3.9) 2.3 (1.3–3.8)
Ly (103 cells/μl) 2.2 (1.0–4.2) 2.2 (1.1–3.1) 2.2 (1.0–3.5) 2.2 (1.3–3.8)
Mo (103 cells/μl) 0.5 (0.2–0.7) 0.4 (0.2–0.7) 0.5 (0.2–0.9) 0.5 (0.3–0.8)
Eo (103 cells/μl) 0.4 (0.1–1.8) 0.4 (0.1–2.2) 0.5 (0.1–1.7) 0.4 (0.1–1.3)
Ba (103 cells/μl) 0.04 (0.02–0.30) 0.04 (0–0.10) 0.04 (0.01–0.19) 0.04 (0–0.20)
CD4 (103 cells/mm3) 874 (367–1571) 934 (465–1553) 811 (462–1306) 866 (440–1602)
CD8(103 cells/mm3) 468 (196–988) 505 (195–1068) 486 (201–1104) 472 (262–1167)
CD4% 42 (32–56) 44 (30–56) 41 (29–54) 44 (32–55)
CD8% 23.1(12.4–36.4) 23.5 (17.0–34.8) 24.6 (14.9–44.0) 24.3 (17.5–35.0)
CD4:CD8 ratio 1.8 (1.0–3.1) 1.8 (0.9–3.2) 1.6 (0.8–2.8) 1.8 (0.8–2.8)
ALT (μ/L) 20.5 (4.9–42.4) 17.4 (4.2–65.3) 22.4 (12.0–80.6) 18.9 (10.7–61.3)
AST (μ/L) 26.9 (17.0–59.2) 22.6 (12.0–43.1) 26.7 (12.5–69.3) 22.2 (13.5–48.5)
T-Bil (μmol/L) 13.9 (5.7–62.6) 9.7 (3.7–38.5) 13.8 (5.3–50.7) 11.5 (5.8–36.1)
Creatinine (μmol/L) 66.3 (49.6–103.7) 64.5 (48.0–87.6) 83.1 (54.2–137.8) 70.7 (52.4–96.8)
Glu (mmol/L) 3.8 (2.2–6.6) 3.8 (2.0–7.0) 3.7 (2.1–9.0) 3.8 (2.1–6.0)
BUN (mmol/L) 2.5 (1.7–4.1) 2.3 (1.2–4.8) 3.0 (1.8–5.3) 2.8 (1.4–4.5)
doi:10.1371/journal.pone.0123140.t001
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between male and female participants in both adolescent and young adult cohorts with males
having higher values but these differences were not clinically relevant (Table 4). We also ob-
served significant differences in the hematological indices among males by age, with the young
adults having a higher median as compared to adolescents in Hb (15.1 g/dL versus 14.2 g/dL),
Hct (45.4% versus 42.6%), RBC (5.4X106/ μL versus 5.2 X106/ μL), ALT (17.4 μ/L versus
16.4 μ/L), creatinine (93 μmol/L versus 65 μmol/L) and neutrophils (2.6X103/ μL versus
2.2X103/ μL). Compared to the males, there was little variation in these parameters among fe-
male adolescent and adult participants except creatinine. However, females had significantly
higher PLT, lymphocytes and WBC than males in both adolescent and young adult cohorts.
There were significant differences in neutrophil counts between male and female adolescents,
Table 2. Adolescent hematological and biochemistry reference values (median and 95th-percentile) comparison between locally-established refer-
ence intervals for western Kenya versus reference values established from the Kisumu Incidence cohort study in western Kenya (2007–2010).
Local interval (Age 13–17 years) [15] This study (Age 16–17 years)
Parameter Male Female Male Female
RBC (106 Cells/μl) 4.9 (4.1–5.8) 4.7 (3.3–5.4) 5.2 (4.3–6.4) 4.9 (3.7–6.0)
Hb (g/dL) 13.1(10.6–15.6) 12.2 (8.1–14.2) 14.2 (11.1–16.7) 12.7 (7.5–14.8)
HCT (%) 38.8 (29.3–48.1) 35.6 (24.8–43.1) 42.6 (33.7–49.7) 38.0 (24.2–43.7)
MCV (fL) 79 (62–92) 78 (57–91) 80.9 (66.2–91.5) 79.0 (52.5–88.5)
PLT (103 cells/μl) 224 (103–386) 233 (134–439) 215 (112–474) 264 (126–448)
WBC(103 cells/μl) 5.6 (3.3–8.3) 5.2 (3.9–10.2) 5.2 (3.6–9.1) 6.0 (3.6–9.5)
Ne (103 cells/μl) 1.9 (0.8–5.0) 2.0 (1.1–3.1) 2.2 (0.9–6.7) 2.7 (1.3–5.8)
Ly (103 cells/μl) 2.2 (1.0–4.2) 2.2 (1.1–3.1) 2.2 (1.4–3.4) 2.5 (1.2–3.9)
Mo (103 cells/μl) 0.5 (0.2–0.7) 0.4 (0.2–0.7) 0.4 (0.2–0.8) 0.5 (0.2–1.1)
Eo (103 cells/μl) 0.4 (0.1–1.8) 0.4 (0.1–2.2) 0.22 (0.03–1.64) 0.24 (0.05–1.4)
Ba (103 cells/μl) 0.04 (0.02–0.30) 0.04 (0–0.10) 0.04 (0.02–0.09) 0.04 (0.02–0.11)
ALT (μ/L) 20.5 (4.9–42.4) 17.4 (4.2–65.3) 16.4 (7.8–33.9) 14.1 (5.7–32.5)
Creatinine (μmol/L) 66.3 (49.6–103.7) 64.5 (48.0–87.6) 65 (39–89) 51 (40–69)
BUN (mmol/L) 2.5 (1.7–4.1) 2.3 (1.2–4.8) 2.7 (1.2–4.5) 2.4 (1.2–4.2)
doi:10.1371/journal.pone.0123140.t002
Table 3. Adult hematological and biochemistry reference values (median and 95th-percentile) comparison between locally-established reference
intervals versus reference values from the Kisumu Incidence cohort study in western Kenya (2007–2010).
Local interval (Age 18–34 years) [15] This study (Age 18–34 years)
Parameter Male (n = 110) Female (n = 132) Male (n = 389) Female (n = 322)
RBC (106 Cells/μl) 5.3 (4.3–6.5) 4.5 (3.4–5.7) 5.4 (4.6–6.6) 4.8 (4.0–5.8)
Hb (g/dL) 14.2 (11.4–16.9) 12.1 (8.0–14.2) 15.1 (12.6–17.2) 12.8 (9.0–14.9)
HCT (%) 41.7 (32.6–51.5) 35.8 (23.2–44.3) 45.4 (38.1–51.6) 38.6 (28.6–44.2)
MCV (fL) 80 (55–98) 79 (60–94) 84.0 (67.4–93.6) 80.4 (59.3–93.2)
PLT (103 cells/μl) 201 (102–307) 220 (88–439) 227 (126–356) 270 (147–454)
WBC(103 cells/μl) 5.3 (2.5–7.4) 5.6 (3.3–9.7) 5.6 (3.3–9.6) 5.9 (3.7–9.1)
Ne (103 cells/μl) 2.0 (0.8–3.9) 2.3 (1.3–3.8) 2.6 (1.3–5.2) 2.7 (1.3–5.0)
Ly (103 cells/μl) 2.2 (1.0–3.5) 2.2 (1.3–3.8) 2.1 (1.2–3.4) 2.3 (1.4–3.8)
Mo (103 cells/μl) 0.5 (0.2–0.9) 0.5 (0.3–0.8) 0.4 (0.2–0.7) 0.4 (0.2–0.8)
Eo (103 cells/μl) 0.5 (0.1–1.7) 0.4 (0.1–1.3) 0.23 (0.04–1.6) 0.21 (0.04–1.2)
Ba (103 cells/μl) 0.04 (0.01–0.19) 0.04 (0–0.20) 0.04 (0.01–0.14) 0.04 (0.02–0.09)
ALT (μ/L) 22.4 (12.0–80.6) 18.9 (10.7–61.3) 17.4 (8.4–54.7) 13.5 (7.2–34.1)
Creatinine (μmol/L) 83.1 (54.2–137.8) 70.7 (52.4–96.8) 93 (69–123) 78 (57–100)
BUN (mmol/L) 3.0 (1.8–5.3) 2.8 (1.4–4.5) 2.8 (1.5–5.0) 2.4 (1.2–4.1)
doi:10.1371/journal.pone.0123140.t003
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with the females having higher counts than males. There were no gender or age differences in
absolute basophil, eosinophil and monocytes counts.
Comparison with locally established reference intervals, US MGH and
NIH-DAIDS toxicity tables
Using the US-based MGH values, most of the KiCoS participants would have been misclassified
as out of range with the highest misclassification in BUN parameter which would result in over
80% of participants excluded (Tables 5 and 6). However, using the locally established reference
intervals, very few of the KiCoS participants would have been misclassified as out of range with
the highest misclassification (<10%) being BUN in both adult and adolescent cohorts except
males in the later (14.5%). Using the US-based MGH values, about a quarter (26.4%) of our
adult female and 7.2% of adult male participants would have been misclassified as having out of
range Hb levels (Table 5). In contrast, using the established reference intervals for western
Kenya, only 1.2% and 1.0% of adult female and male participants would have been misclassified
as having out of range Hb levels. This observation was similar for other red cell indices includ-
ing Hct, MCV and RBC count with higher proportion of female participants misclassified.
Using the 2004 NIH DAIDS toxicity grading to select participants eligible for the study
(Tables 5 and 6), 12.8% (n = 58) of female participants and 1.0% (n = 5) of male participants
would have been classified as having an abnormal Hb level. However, only 2.4% (n = 11) of the
female participants and 1.0% (n = 5) of male participants would have been classified as having
out of range values using the locally established reference intervals. Similarly, 3.4% (n = 17)
male and 1.5% (n = 7) female participants would have been classified as having an abnormal
platelet count using the 2004 NIH DAIDS toxicity grading while only 1.0% (n = 5) male and
Table 4. Test of difference in hematologic and clinical chemistry parameters between gender and age-groups from the 16–34 years old cohort in
Kisumu Kenya (2007–2010).
Age 16–17 years Age 18–34 years
Parameter Gender n median p-value (gender) n median p-value (gender) P-value (age)
Hemoglobin (g/dL) Female 132 12.7 (7.5–14.8) <0.0001 322 12.8 (9.0–14.9) <0.0001 0.3143
Male 110 14.2 (11.1–16.7) 389 15.1 (12.6–17.2) <0.0001
Hematocrit (%) Female 132 38.0 (24.2–43.7) <0.0001 322 38.6 (28.6–44.2) <0.0001 0.2242
Male 110 42.6 (33.7–49.7) 389 45.4 (38.1–51.6) <0.0001
WBC (x1000) Female 132 6.0 (3.6–9.5) 0.0025 322 5.9 (3.7–9.1) 0.0002 0.4387
Male 110 5.2 (3.6–9.1) 389 5.6 (3.3–9.6) 0.5766
RBC (x1012/L) Female 132 4.9 (3.7–6.0) <0.0001 322 4.8 (4.0–5.8) <0.0001 0.4424
Male 110 5.2 (4.3–6.4) 389 5.4 (4.6–6.6) <0.0001
Lymphocytes (x109/L) Female 132 2.5 (1.2–3.9) 0.0112 322 2.3 (1.4–3.8) <0.0001 0.0789
Male 110 2.2 (1.4–3.4) 389 2.1 (1.2–3.4) 0.0261
Neutrophiles (x109/L) Female 132 2.7 (1.3–5.8) 0.0112 322 2.7 (1.3–5.0) 0.0538 0.4565
Male 110 2.2 (0.9–6.7) 389 2.6 (1.3–5.2) 0.0169
PLT(x109/L) Female 132 264 (126–448) <0.0001 322 270 (147–454) <0.0001 0.3589
Male 110 215 (112–474) 389 227 (126–356) 0.1218
ALT (μ/L) Female 132 14.1 (5.7–32.5) 0.0030 322 13.5 (7.2–34.1) <0.0001 0.2750
Male 110 16.4 (7.8–33.9) 388 17.4 (8.4–54.7) 0.0417
BUN (mmol/L) Female 132 2.4 (1.2–4.2) 0.0241 322 2.4 (1.2–4.1) <0.0001 0.7883
Male 110 2.7 (1.2–4.5) 388 2.8 (1.5–5.0) 0.0604
Creatinine (μmol/L) Female 132 51 (40–69) <0.0001 322 78 (57–100) <0.0001 <0.0001
Male 110 65 (39–89) 388 93 (69–123) <0.0001
doi:10.1371/journal.pone.0123140.t004
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0.7% (n = 3) female participants would have been classified as out of range using the estab-
lished reference interval for western Kenya.
Discussion
With increasing clinical trials in Africa in an effort to combat tropical diseases [24], a need
arises to consider the health status of the likely participants in such studies [12]. In this regard,
several African studies have generated reference intervals for use in the respective regions
[13, 15, 24, 25]. While it is important to develop locally derived reference intervals that ensure
proper assessment of volunteers in clinical trials, monitoring of laboratory-based adverse
events and prevention of unnecessary exclusion, it is important to evaluate their use within the
local population. To our knowledge, this is one of the first evaluations of established reference
intervals reported in sub-Saharan Africa. In this study, we evaluate the use of hematological
and biochemistry reference intervals established for western Kenya using specimen drawn
from participants in a HIV incidence cohort study in Kisumu. Our values were comparable to
those of the established reference intervals for most parameters although our median values
were slightly higher for most hematological parameters. This may be so given that the samples
Table 5. Out of range and frequency of adverse events in the Kisumu Adult cohort obtained from comparison with values from locally-established
reference intervals, DAIDS and North American derived MGH values.
Out of range
comparison
This Study Local reference
[15]
MGH-USA [9] 2004 DAIDS
[17]




n % 95% reference
interval
n % Cut-off N %
Hemoglobin (g/dL) Female 9.0–14.9 322 8.0–14.2 4 1.2 12–16 85 26.4 >10.9 40 12.4
Male 12.6–17.2 389 11.4–16.9 4 1.0 13.5–17.5 28 7.2 >10.9 3 0.8
Hematocrit (%) Female 28.6–44.2 322 23.2–44.3 2 0.6 36–46 83 25.8
Male 38.1–51.6 389 32.6–51.5 3 0.8 41–53 37 9.5
MCV (%) Female 59.3–93.2 322 60–94 12 3.7 80–100 153 47.5
Male 67.4–93.6 389 55–98 3 0.8 80–100 103 26.5
WBC (x109/L) Female 3.7–9.1 322 3.3–9.7 8 2.5 4.5–11.0 37 11.5 >2.5 1 0.3
Male 3.3–9.6 389 2.5–7.4 0 0 4.5–11.0 82 21.1 >2.5 0 0
RBC (x1012/L) Female 4.0–5.8 322 3.4–5.7 1 0.3 4.0–5.2 7 2.2
Male 4.6–6.6 389 4.3–6.5 2 0.5 4.2–6.3 2 0.5
Lymphocytes (x109/
L)
Female 1.4–3.8 322 1.3–3.8 7 2.2 1.0–4.8 0 0
Male 1.2–3.4 389 1.0–3.5 4 1.0 1.0–4.8 4 1.0
Neutrophils (x109/L) Female 1.3–5.0 322 1.3–3.8 10 3.1 1.8–7.7 0 0 >1.3 10 3.3
Male 1.3–5.2 389 0.8–3.9 0 0 1.8–7.7 4 1.0 >1.3 13 4.0
PLT (x109/L) Female 147–454 322 88–439 1 0.3 150–350 12 3.7 125 4 1.2
Male 126–356 389 102–307 4 1.0 150–350 30 7.7 125 8 2.1
Eosinophils (103
cells/μl)
Female 0.04–1.2 322 0–1.3 7 2.2 0–0.5 52 16.1
Male 0.04–1.6 389 0–1.7 5 1.3 0–0.5 77 19.8
ALT (μ/L) Female 7.2–34.1 322 0–61.3 1 0.3 0–35 7 2.2 <76.6 0 0
Male 8.4–54.7 389 0–80.6 4 1.0 0–35 39 10.0 <100.8 2 0.5
BUN (mmol/L) Female 1.2–4.1 322 1.4–4.5 23 7.1 3.6–7.1 305 94.7
Male 1.5–5.0 389 1.8–5.3 32 8.2 3.6–7.1 324 83.3
Creatinine (μmol/L) Female 57–100 322 0–96.8 18 5.6 0–133 0 0 <106.5 4 1.2
Male 69–123 389 0–137.8 2 0.5 0–133 2 0.5 <151.6 1 0.3
doi:10.1371/journal.pone.0123140.t005
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for this evaluation were drawn from an urban population that may have had access to better
healthcare, clean water and nutrition than the rural population from where the established ref-
erence intervals for western Kenya [15] were obtained. Moreover, using the US MGH reference
interval, the overall out of range MCV values constituted 54.0% [15] of the study population in
rural western Kenya but only 27.6% in this study. Low MCV is an indirect marker of iron defi-
ciency [26]. This is further corroborated by the low eosinophil counts observed in this study.
Our eosinophil counts are comparable to those obtained from an urban population of blood
donors in Uganda [18] in contrast to higher counts in a similar study in a rural population in
the same country [27]. Our values for ALT and creatinine were also lower than those of Zeh
et al [15]. Similarly, a study in Cameroon designed to establish reference intervals for biochem-
ical parameters reported statistical differences in biochemistry reference parameters between
participants from urban and rural geographic regions [28]. While this might not necessitate
the need to establish separate intervals, consideration should be made when applying such in-
tervals within specific populations.
Using the US-based MGH reference intervals to hypothetically select participants in a trial
based on Hb, WBC counts, neutrophil counts, eosinophil counts and platelets, 51.5% (n = 491)
of the total participants would have been excluded from participating in the study (Table 7).
Table 6. Out of range and frequency of adverse events in the Kisumu Adolescent cohort obtained from comparison with values from locally-estab-
lished reference intervals and DAIDS values.
Out of range
comparison
This Study Local reference
[15]
MGH-USA [9] 2004 DAIDS
[17]




n % 95% reference
interval
n % Cut-off N %
Hemoglobin (g/dL) Female 7.5–14.8 132 8.1–14.2 7 5.3 12–16 37 28.0 >10.9 18 13.6
Male 11.1–16.7 110 10.6–15.6 1 0.9 13.5–17.5 36 32.7 >10.9 2 1.8
Hematocrit (%) Female 24.2–43.7 132 24.8–43.1 2 1.5 36–46 30 22.7
Male 33.7–49.7 110 29.3–48.1 2 1.8 41–53 41 37.3
MCV (%) Female 59.3–93.2 132 57–91 6 4.5 80–100 76 57.6
Male 67.4–93.6 110 62–92 1 0.9 80–100 48 43.6
WBC (x109/L) Female 3.6–9.5 132 3.9–10.2 3 2.3 4.5–11.0 12 9.1 >2.5 3 2.3
Male 3.6–9.1 110 3.3–8.3 0 0 4.5–11.0 27 24.5 >2.5 0 0
RBC (x1012/L) Female 3.7–6.0 132 3.3–5.4 1 0.8 4.0–5.2 4 3.0
Male 4.3–6.4 110 4.1–5.8 2 1.8 4.2–6.3 2 1.8
Lymphocytes
(x109/L)
Female 1.2–3.9 132 1.1–3.1 4 3.0 1.0–4.8 2 1.5
Male 1.4–3.4 110 1.0–4.2 0 0 1.0–4.8 0 0
Neutrophiles
(x109/L)
Female 1.3–5.8 132 1.1–3.1 3 2.3 1.8–7.7 20 15.2 >1.3 3 2.3
Male 0.9–6.7 110 0.8–5.0 0 0 1.8–7.7 27 24.5 >1.3 9 8.2
PLT (x109/L) Female 126–448 132 134–439 2 1.5 150–350 6 4.5 125 3 2.3
Male 112–474 110 103–386 1 0.9 150–350 14 12.7 125 8 7.3
Eosinophils (103
cells/μl)
Female 0.04–1.2 132 0–2.2 1 0.8 0–0.5 24 18.2
Male 0.04–1.6 110 0–1.8 0 0 0–0.5 22 20.0
ALT (μ/L) Female 5.7–32.5 132 0–65.3 1 0.8 0–35 3 2.3 <76.6 0 0
Male 7.8–33.9 110 0–42.4 1 0.9 0–35 2 1.8 <100.8 0 0
BUN (mmol/L) Female 1.2–4.2 132 1.2–4.8 4 3.0 3.6–7.1 116 87.9
Male 1.2–4.5 110 1.7–4.1 16 14.5 3.6–7.1 96 87.3
Creatinine (μmol/L) Female 40–69 132 0–87.6 0 0 0–133 0 0 <106.5 0 0
Male 39–89 110 0–103.7 0 0 0–133 0 0 <151.6 0 0
doi:10.1371/journal.pone.0123140.t006
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However, using the established reference intervals for western Kenya, only 6.7% (n = 64) of
participants would have been excluded from participating in the study. Including BUN in the
selection criteria would result in exclusion of over 80% of participants. This was similar in
other African studies [7, 13, 15, 27] suggesting that this may result from a common environ-
mental or genetic factor [12, 13]. Thus use of locally established reference intervals would re-
duce the overall screening to enrollment ratio in this case. This reduces the overall cost of
screening and theoretically would reduce the time period for screening by reaching the study
target within a shorter time period. Eller et al. have documented similar findings in a study of
healthy adult Ugandan blood donors [18]. It is not surprising to see that the adolescent cohort
resulted in the most out of range values hence yielded the least enrolled participants using the
western-derived reference intervals and toxicity tables. Thus, partitioning of male adolescents
needs to be considered in future trials.
Similarly, using the 2004 NIH US DAIDS toxicity grading for screening, 31.0% (n = 295) of
participants would have been excluded from the study. Although the table has been revised for
some parameters including neutropenia [29], a large proportion of our study participants
would still have been excluded based on Hb levels. Moreover, the toxicity table does not take
into account the significant difference in red blood cell parameters between males and females,
thus, a majority of those excluded would constitute female participants.
The CLSI guidelines recommend the collection of specimen from healthy volunteers for use
in validating reference intervals. Thus, a limitation of this study was the failure to screen for
possible asymptomatic parasitic infections like malaria and helminthes which are endemic
within the study region. However, our Hb values were much higher than those from a study
within the same region that screened out malaria infected participants [13]. Moreover, our eo-
sinophil counts were much lower than the two studies within the region which screened partic-
ipants from a rural population [13, 15]. A second limitation may have been that this was a self-
selected population of participants willing to participate in a cohort study. However, this repre-
sents a similar population that would be willing to participate in a clinical trial thus provides a
good sample to evaluate the use of the locally established reference intervals. Moreover, the
HIV prevalence of the study population (12.0%) is comparable to the prevalence within the
general population [30].
Given that the number of clinical trials and persons receiving clinical services is expected to
increase substantially in sub-Saharan Africa, there is a need for the establishment and evalua-
tion of locally derived clinical laboratory reference values to ensure appropriate general health
assessment, treatment monitoring, and efficient implementation of clinical trials. Even more
important is the need for the establishment of toxicity grading tables for application in clinical
care among Africans based on the documented differences between laboratory reference inter-
vals from African and Caucasian populations. This study confirms that the hematological and
Table 7. Hypothetical enrollment using local reference intervals compared to US-derived reference intervals and the DAIDS toxicity tables.
Number (%) Enrolled
Age category Sex No of participants Local intervals [15] US MGH [9] *DAIDS [17]
Adolescents Male 110 106 (96.4%) 27 (24.5%) 70 (63.6%)
Female 132 113 (85.6%) 67 (50.8%) 81 (61.4%)
Adults Male 389 374 (96.1%) 196 (50.4%) 289 (74.3%)
Female 322 296 (92.0%) 172 (53.4%) 218 (67.7%)
Total 953 889 (93.3%) 462 (48.5%) 658 (69.0%)
* eosinophil count grading using US derived values for adults.
doi:10.1371/journal.pone.0123140.t007
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biochemistry reference intervals established by Zeh et al. are valid for use in participant recruit-
ment in western Kenya.
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